ClinicalTrials.gg
TerminatedNCT07040059Updated Apr 17, 2026

A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

A Phase 1/2 interventional study of AUR103 Calcium and Trastuzumab + CAPOX (Capecitabine + Oxaliplatin) in HER 2 Positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Aurigene Discovery Technologies Limited. Terminated at 8 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Patient recruitment problems.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Stomach Neoplasms with a site in India — 7 open to participants now, 9 under way, 5 of them phase 3. Stomach Neoplasms · India.

Enrollment
17th of 17
2 · median 584
Started
2025
with 1 other
Phase 1/2
Only one
of the 22
Registered
19th of 22
by date
Lead sponsor
3 of 22
Aurigene Discovery Technologies Limited

Among the 22 studies in Stomach Neoplasms with a site in India, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 1/2, and was the 19th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 22 studies in Stomach Neoplasms with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stomach Neoplasms with a site in India, or all of them as a file.
02

Study summary

The study will have a dose escalation part (Phase 1b) and a randomized part (Phase 2). In Phase 1b, patients diagnosed with advanced HER2 positive gastric/gastroesophageal adenocarcinoma will be enrolled in a 3 + 3 design dose escalation manner to evaluate the safety, efficacy, PK/PD of AUR103 Calcium when administered in combination with Trastuzumab and CAPOX (capecitabine and oxaliplatin). Phase 2 is a randomization study. The primary objective of the phase 2 study is to assess the efficacy of AUR103 Calcium when administered in combination with Trastuzumab and CAPOX (capecitabine and oxaliplatin). The phase 2 of the study will be conducted after Phase 1b.

Read the detailed description

This study (AUR103-201; BHARAT-2) will be conducted in patients with HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma, in the first-line setting. In the study Part 1 (Phase 1b), the safety and tolerability of AUR103 calcium will be evaluated in combination with Trastuzumab and CAPOX. In the study part 1 (Phase 1b), there will 3 cohorts; Cohort 1 patients will receive the study drug (AUR103 Calcium) at 200 mg BID dose along with standard doses of trastuzumab, and CAPOX (capecitabie and oxaliplatin), Cohort 2 patients will receive the study drug (AUR103 Calcium) at 300 mg BID dose along with standard doses of trastuzumab, and CAPOX, and Cohort 3 patients will receive the study drug (AUR103 Calcium) at 400 mg BID dose along with standard doses of trastuzumab, and CAPOX.

In the study Part 2 (Phase 2), the efficacy of AUR103 calcium in combination with Trastuzumab and CAPOX will be evaluated in HER2-positive gastric or gastroesophageal junction adenocarcinoma patients. The part 2 (Phase 2) of the study will be a randomized study which will start after part 1 (Phase 1b). In the study part 2 (Phase 2), there will either 1 or 2 treatment arm(s) and one control arm (Trastuzumab + CAPOX). The number treatment arms will be based on the phase 1b data. However, the treatment patients in the Phase 2 will receive the study drug along with Trastuzumab and CAPOX.

03

Conditions studied

  • HER 2 Positive Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • BHARAT 2
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide signed and dated and agree to comply with all study related activities.
  2. Male or female patients aged greater than or equal to 18 years.
  3. Patients must meet the following criteria for each of the respective parts of the study:

    a) Pathological diagnosis of a -positive, unresectable locally advanced or , gastric / gastroesophageal (GE) junction adenocarcinoma.

    [Note: For patients who have already undergone HER2 testing, it does not need to be repeated. For patients who have not undergone HER2 testing, the same can be done as part of pre-screening, after taking informed consent].

    B) Patients must NOT have received any systemic anti-cancer therapy for the treatment of gastric or gastroesophageal (GE) junction adenocarcinoma.

    [Note: The partial resection of tumor or debulking surgery is allowed but any therapeutic chemotherapy or systemic anti-cancer therapy is not allowed].

  4. (ECOG) Performance status of 0 or 1.
  5. Acceptable bone marrow as described below:

    1. ANC greater than or equal to 1500/μL (without WBC growth factor support).
    2. count greater than or equal to 100,000/μL (without transfusion support).
    3. greater than or equal to 9 g/dL (Transfusion is allowed to achieve this Hb).
  6. Acceptable organ function as described below:

    1. Total less than or equal to 1.5 x (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin less than or equal to 2.5 x ULN).
    2. (SGOT) less than or equal to 3 x ULN (less than or equal to 5 × ULN if known liver metastases).
    3. ALT (SGPT) less than or equal to 3 x ULN (less than or equal to 5 × ULN if known liver metastases).
    4. (CrCl) greater than or equal to 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). (Cockcroft-Gault formula for estimated creatinine clearance [eCrCl]: eCrCl = [140 - Age] × Weight [kg] × [0.85 if Female] / [72 × serum creatinine (mg/dL)]).
    5. Albumin greater than or equal to 3.0 g/dL.
  7. Evidence of as per (RECIST) version 1.1 [Note: Measurable disease for solid tumors is defined as at least one lesion that can be accurately measured in at least 1 dimension with a minimum size of 10 mm for non-nodal lesions or 15 mm in short axis for nodal lesions].
  8. Patients who have not undergone HER2 testing must be willing and able to provide an adequate archived tumor tissue sample or a fresh tumor tissue sample to confirm HER2 status.

    [Note: If archived sample is not available, and HER2 testing has not been done, then patient must agree to submit fresh tumor sample for an assessment of HER2 status].

  9. (LVEF) greater than or equal to 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan at Screening.
  10. Ability to swallow and retain oral medications.
  11. Negative serum pregnancy test in women of (WOCBP).
  12. Women of childbearing potential and men who partner with such a woman of childbearing potential must agree to use one or more of highly effective method(s) for for the duration of the study, i.e., through 28-day follow up visit, after discontinuation of study drug(s).

Exclusion criteria

Exclusion Criteria:

  1. Patients with resectable gastric / gastroesophageal (GE) junction adenocarcinoma.
  2. Exposed to definitive radiotherapy [Note: Palliative radiotherapy is allowed].
  3. Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  4. Known central nervous system (CNS) .
  5. Major surgery less than or equal to 28 days from Cycle 1 Day 1 (Major surgery is defined as a procedure requiring general anaesthesia).
  6. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
  7. Known active or chronic or infection.
  8. Uncontrolled congestive heart failure ( [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
  9. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
  10. The (corrected QT interval Fridericia method) value in the screening more than 460 ms in males and females.
  11. Currently taking warfarin or other oral coumarin-derivative anticoagulant therapy.
  12. Patients with peripheral neuropathy of Grade greater than or equal to 2.
  13. Patients with severe obstructive pulmonary disease, pulmonary fibrosis, or interstitial lung disease.
  14. Patients with poorly controlled hypertension, defined as systolic blood pressure more than or equal to 160 mmHg or diastolic blood pressure more than 100 mmHg.
  15. Previous or concomitant additional , except for basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix; patients with other malignancies are eligible if they have remained disease free for at least 2 years prior to trial entry and in the opinion of the investigator deemed to have a low likelihood of recurrence.
  16. Any medical, psychiatric, or social condition; or laboratory abnormality that may increase the risk of trial participation or may interfere with the process and/or with compliance with the requirements of the trial or may interfere with the interpretation of the trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.
  17. Pregnant or lactating women.
  18. Current swab-positive or suspected (under investigation) COVID19 infection or fever and other signs or symptoms suggestive of COVID-19 infection with recent contact of person(s) with confirmed COVID-19 infection, at screening or Cycle 1 Day 1.
  19. Patients with any known to receive trastuzumab, or capecitabine, or oxaliplatin.
  20. Known to trastuzumab, capecitabine, oxaliplatin, or to any of its components.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Phase 1b (Cohort 1: AUR103 Calcium 200 mg BID with standard dose of Trastuzumab and CAPOX.

    Phase 1b: Cohort 2 (AUR103 Calcium 300 mg BID with standard dose of Trastuzumab and CAPOX). Cohort 2 of Phase 1b will start after completion of dose-limiting toxicity (DLT) period of Cohort 1.

    Drug: AUR103 Calcium

  • Experimental
    Phase 2 Treatment Arm

    Phase 2 (Experimental Arm) - Either one or two treatment arm(s) selected from the Phase 1b part.

    Drug: AUR103 Calcium

  • Active comparator
    Phase 2 Control Arm

    Phase 2 will have control arm (with standard dose of Trastuzumab and CAPOX).

    Drug: Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)

  • Experimental
    Phase 1b (Cohort 2: AUR103 Calcium 300 mg BID with standard dose of Trastuzumab and CAPOX.

    Drug: AUR103 Calcium

  • Experimental
    Phase 1b: Cohort 3 (AUR103 Calcium 400 mg BID with standard dose of Trastuzumab and CAPOX).

    Phase 1b: Cohort 3 (AUR103 Calcium 400 mg BID with standard dose of Trastuzumab and CAPOX). Cohort 3 of Phase 1b will start after completion of dose-limiting toxicity (DLT) period of Cohort 2.

    Drug: AUR103 Calcium

Interventions

  • DrugAUR103 Calcium

    AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).

    Also known as: Trastuzumab, Capecitabine

  • DrugTrastuzumab + CAPOX (Capecitabine + Oxaliplatin)

    Drug page: Trastuzumab

    Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.

    Also known as: Trastuzumab, Capecitabine

06

What researchers measure

Primary outcomes

  1. Part 1 (Safety): Treatment Emergent Adverse Events (TEAEs)

    TEAEs will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 5.0)

    Time frame: Through the study completion, an average of 1 year

  2. Part 1 (Pharmacokinetics): Area under the curve (AUC)

    Area under the curve of AUR103 Calcium

    Time frame: On Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent cycle through study completion, for an average duration of one year.

  3. Part 1 (Pharmacokinetics): Maximum concentration

    Maximum concentration of AUR103 Calcium

    Time frame: On Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent cycle through study completion, for an average duration of one year.

  4. Part 1 (Pharmacokinetics): Time to Maximum concentration

    Time to Maximum concentration of AUR103 Calcium

    Time frame: On Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent cycle through study completion, for an average duration of one year.

  5. Part 1 (Pharmacokinetics): Terminal elimination half life

    Terminal elimination half-life of AUR103 Calcium

    Time frame: On Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent cycle through study completion, for an average duration of one year.

  6. Part 2 (Efficacy): Best Objective Tumor Response Rate (ORR)

    Best Objective Tumor Response Rate (ORR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

Secondary outcomes

  1. Part 1 (Efficacy): Best Objective Tumor Response Rate (ORR)

    ORR will be assessed during the study during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  2. Part 1 (Efficacy): Duration of response (DoR)

    Duration of response (DoR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  3. Part 1 (Efficacy): Time to Objective Tumor Response

    Time to Objective Tumor Response will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  4. Part 1 (Efficacy): Duration of Clinical Benefit Rate (CBR)

    Duration of Clinical Benefit Rate (CBR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  5. Part 1 (Efficacy): Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  6. Part 1 (Efficacy): Progression Free Survival (PFS)

    Progression Free Survival (PFS) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  7. Part 1 (Efficacy): Time to progression

    Time to progression will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  8. Part 1 (Efficacy): Overall survival (OS)

    Overall survival will be assessed during the study

    Time frame: Through study completion, an average of 1 year

  9. Part 2 (Efficacy): Duration of response

    Duration of response will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  10. Part 2 (Efficacy): Time to Objective Tumor Response

    Time to Objective Tumor Response will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  11. Part 2 (Efficacy): Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  12. Part 2 (Efficacy): Duration of Clinical Benefit Rate (CBR)

    Duration of Clinical Benefit Rate (CBR) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  13. Part 2 (Efficacy): Progression Free Survival (PFS)

    Progression Free Survival (PFS) will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  14. Part 2 (Efficacy): Time to progression

    Time to progression will be assessed during the study

    Time frame: Every 3 cycle, through study completion, for an average duration of one year.

  15. Part 2 (Efficacy): Overall survival (OS)

    Overall survival will be assessed during the study

    Time frame: Through study completion, an average of 1 year

  16. Part 2 (Safety): Treatment Emergent Adverse Events (TEAEs)

    Treatment Emergent Adverse Events (TEAEs) will be assessed throughout the study duration

    Time frame: Through study completion, an average of 1 year

  17. Part 2 (Health Related Quality of Life): EORTC QLQ-C30

    Health Related Quality of Life will be assessed by EORTC QLQ-C30 questionaire

    Time frame: Cycle 1 Day 1 and Day 1 of each subsequent cycle through study completion, for an average duration of one year.

  18. Part 2 (Health Related Quality of Life): EORTC-QLQ-STO22 score

    Health Related Quality of Life will be assessed by EORTC-QLQ-STO22 score

    Time frame: Cycle 1 Day 1 and Day 1 of each subsequent cycle through study completion, for an average duration of one year.

07

Study locations

8 sites
  • HCG Cancer Center
    Vizag, Andhra Pradesh 530040, India
  • Shalby Hospital
    Ahmedabad, Gujarat 380015, India
  • The Gujarat Cancer & Research Insititute
    Ahmedabad, Gujarat 380016, India
  • Kiran Hospital Multi Super Speciality Hospital & Reseach Center
    Surat, Gujarat 395004, India
  • Asha Hospital and Research Centre
    Bangalore, Karnataka 560076, India
  • Karnataka Cancer Hospital and Radiation Theraphy Center
    Bangalore, Karnataka 560096, India
  • Netaji Subhas Chandra Bose Cancer Hospital
    Kolkata, West Bengal 700094, India
  • Hope & Heal Cancer Hospital and Research Center
    Siliguri, West Bengal 734015, India
08

References and documents

Individual participant data

Plan to share: No — Due to ethical concerns.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 26, 2025
StartActual
Mar 22, 2025
Primary completionActual
Dec 29, 2025
CompletionActual
Dec 29, 2025
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07040059
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Mar 22, 2025
Primary completion
Dec 29, 2025
Completion
Dec 29, 2025
Last update
Apr 17, 2026

Study contacts

Akhil Kumar
principal investigator · Aurigene Oncology Limited

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion